CY1110205T1 - IMMUNE COMPOSITION AND METHODS - Google Patents

IMMUNE COMPOSITION AND METHODS

Info

Publication number
CY1110205T1
CY1110205T1 CY20101100663T CY101100663T CY1110205T1 CY 1110205 T1 CY1110205 T1 CY 1110205T1 CY 20101100663 T CY20101100663 T CY 20101100663T CY 101100663 T CY101100663 T CY 101100663T CY 1110205 T1 CY1110205 T1 CY 1110205T1
Authority
CY
Cyprus
Prior art keywords
subject
composition
methods
expression
direct
Prior art date
Application number
CY20101100663T
Other languages
Greek (el)
Inventor
John H Eldridge
Zimra R Israel
Michael A Egan
Stephen A Udem
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04722764A external-priority patent/EP1605971B1/en
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CY1110205T1 publication Critical patent/CY1110205T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Μία μέθοδος επαγωγής μιας αντίγονο ειδικής απόκρισης σε ένα άτομο θηλαστικού περιλαμβάνει τα στάδια χορήγησης στο άτομο μιας αποτελεσματικής ποσότητας μιας πρώτης σύνθεσης που περιλαμβάνει ένα DNA πλασμίδιο που περιέχει μία DNA αλληλουχία η οποία κωδικεύει ένα αντιγόνο υπό τον έλεγχο ρυθμιστικών αλληλουχιών που κατευθύνουν την έκφραση αυτής σε ένα κύτταρο θηλαστικού ή σπονδυλωτού. Η μέθοδος περιλαμβάνει επίσης την χορήγηση στο άτομο μιας δεύτερης σύνθεσης η οποία περιλαμβάνει έναν ανασυνδυασμένο ιό θυλακιώδους στοματίτιδας (VSV) που περιέχει μία αλληλουχία νουκλεϊνικού οξέος η οποία κωδικεύει το αντιγόνο υπό τον έλεγχο ρυθμιστικών αλληλουχιών που κατευθύνουν την έκφραση αυτής σε ένα κύτταρο θηλαστικού ή σπονδυλωτού. Ο rVSV είναι σε μία υλοποίηση ικανός για αναδιπλασιασμό. Τα κιτ για χρήση σε ανοσοποιητικές και θεραπευτικές αγωγές της νόσου περιλαμβάνουν τα συστατικά και τις μεθόδους για την πρακτική εφαρμογή αυτής της μεθόδου.One method of inducing an antigen specific response in a mammalian subject comprises the steps of administering to the subject an effective amount of a first composition comprising a DNA plasmid containing a DNA sequence encoding an antigen under the control of regulatory sequences that direct its expression to a mammalian or vertebrate cell. The method also comprises administering to the subject a second composition comprising a recombinant follicular stomatitis virus (VSV) containing a nucleic acid sequence which encodes the antigen under the control of regulatory sequences that direct its expression to a cell. RVSV is in one embodiment capable of replication. Kits for use in immune and therapeutic treatments of the disease include the ingredients and methods for practicing this method.

CY20101100663T 2003-03-26 2010-07-15 IMMUNE COMPOSITION AND METHODS CY1110205T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45787603P 2003-03-26 2003-03-26
US54673304P 2004-02-23 2004-02-23
EP04722764A EP1605971B1 (en) 2003-03-26 2004-03-23 Immunogenic composition and methods

Publications (1)

Publication Number Publication Date
CY1110205T1 true CY1110205T1 (en) 2015-01-14

Family

ID=33313369

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100663T CY1110205T1 (en) 2003-03-26 2010-07-15 IMMUNE COMPOSITION AND METHODS

Country Status (7)

Country Link
JP (1) JP5635950B2 (en)
KR (1) KR101059721B1 (en)
CN (1) CN102085377B (en)
CY (1) CY1110205T1 (en)
DE (1) DE602004027359D1 (en)
ES (1) ES2345198T3 (en)
PT (1) PT1605971E (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662885A (en) * 2020-06-22 2020-09-15 扬州大学 Construction, rescue and application of infectious clone of virulent and attenuated strains of two highly homologous genome porcine reproductive and respiratory syndrome viruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
WO2002097091A1 (en) * 2001-05-29 2002-12-05 University Of Miami Generation of hcv-like particles and chimeric hcv virus
US20070134200A1 (en) * 2003-03-26 2007-06-14 Wyeth Immunogenic composition and methods

Also Published As

Publication number Publication date
DE602004027359D1 (en) 2010-07-08
CN102085377B (en) 2014-03-12
KR20060002872A (en) 2006-01-09
CN102085377A (en) 2011-06-08
ES2345198T3 (en) 2010-09-17
JP2011251979A (en) 2011-12-15
JP5635950B2 (en) 2014-12-03
KR101059721B1 (en) 2011-08-29
PT1605971E (en) 2010-07-29

Similar Documents

Publication Publication Date Title
BRPI0408779A (en) use of compositions, immunogenic composition and kit
UY39060A (en) COMPOSITIONS AND METHODS TO PREVENT AND TREAT CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
Chang et al. Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model
CY1115749T1 (en) SWINE CYCLE, NUCLEAR ACIDS, POLYPALPTES AND VACCINES
ES2059565T3 (en) MVA VIRUSES OF THE VACCINE, RECOMBINANT.
DE68924162D1 (en) STRESS PROTEINS AND USES THEREFOR.
WO2002080851A3 (en) Chimeric vaccines
DK0561890T3 (en) DNA expression systems based on alphaviruses
ES2185762T3 (en) VACCINES AGAINST THE PESTE.
DE60044665D1 (en) HER2 / NEW FUSION PROTEINS
EA202090759A3 (en) CORE PROTEIN OF HEPATITIS B VIRUS AND SURFACE ANTIGENIC PROTEIN AND THEIR VACCINE
CY1114643T1 (en) MODULAR CELLS NM-F9 (DSM ACC2606) AND NM-D4 (DSM ACC2605), USE OF THESE
DA’Dara et al. A DNA‐prime/protein‐boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection
MX2011012807A (en) Compositions and methods for administration of vaccines against dengue virus.
AR041964A1 (en) HCV VACCINE UNDERSTANDING A POLINUCLEOTIDE
ATE473236T1 (en) ANTIGENS OF PISCIRICKETTSIA SALMONIS AND THEIR USE
ATE547529T1 (en) MATERIALS AND METHODS RELATED TO IMPROVED VACCINATION STRATEGIES
ES2196032T3 (en) MUTANTS AND VACCINES OF THE VIRUSES OF THE INFECTIOUS ANEMIA OF THE CHICKENS AND USES BASED ON THE VIRAL PROTEINS VP1, VP2 AND VP3 OR SEQUENCES OF SUCH VIRUS CODING THEM.
AR009365A1 (en) FMD VIRUS VACCINES (FMDV), PEPTIDES, DNA SEQUENCES AND THE USE OF PEPTIDES IN DETECTION SYSTEMS AND THE USE OF FMDC VACCINE FOR PREPARATION OF A COMPOSITION TO IMMUNIZE PIGS AND CATTLE
CY1110205T1 (en) IMMUNE COMPOSITION AND METHODS
BR0206112A (en) Nucleic acid vaccines using tumor antigen-encoding nucleic acids with cytokine helper-encoding nucleic acid
CO2023014970A2 (en) Coronavirus vaccine comprising a mosaic protein
ATE319833T1 (en) VACCINES TO INCREASE IMMUNE RESPONSES AGAINST HERPES SIMPLEX VIRUS
CY1105947T1 (en) MYCOPLASMA HYOPNEUMONIAE MHP3 GENE NUCLEIC ACIDS AND PROTEINS AND USES THEREOF
BRPI0209416A2 (en) New expression vectors and their use